HC Wainwright & Co. Maintains Buy on Genmab, Raises Price Target to $50
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju has reaffirmed a Buy rating on Genmab (NASDAQ:GMAB) and increased the price target from $49 to $50.
January 29, 2024 | 11:40 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Genmab's Buy rating is maintained by HC Wainwright & Co., with a raised price target from $49 to $50, indicating a positive outlook on the stock.
The increase in price target by a reputable analyst typically signals confidence in the company's future performance and can lead to increased investor interest and a potential short-term rise in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100